Linking a Single Dominant Antibody to HIT: A Novel Study Led by Ishac Nazy, Donald Arnold, and John G. Kelton
Mark Crowther, Distinguished University Professor and Chair, Department of Medicine at McMaster University, shared on LinkedIn:
”McMaster’s Department of Medicine: New Insight into a Life-Threatening Blood Disorder, Led by McMaster Researchers
A paper published last week in the New England Journal of Medicine has reshaped how we understand heparin-induced thrombocytopenia (HIT)—a serious reaction to a widely used blood thinner.
Researchers from McMaster Faculty of Health Sciences and the McMaster University Department of Medicine have found that, contrary to decades of belief, a single monoclonal antibody is responsible for triggering HIT.
This key discovery suggests the condition is not a polyclonal immune response, as previously thought, but rather driven by one dominant antibody—an insight that could significantly improve diagnostic precision and lead to more targeted therapies.
The study was led by Dr. Ishac Nazy, PhD, Professor in the Department of Medicine and John G. Kelton Chair in Immunological Blood Disorders and and Dr Donald Arnold.
Their team includes investigators from the McMaster Platelet Immunology Laboratory and the Michael G. DeGroote Centre for Transfusion Research.
Dr. Nazy notes: ‘Our findings correct a long-standing misunderstanding of HIT and point toward more accurate and safer testing methods.’
This work underscores McMaster’s continued leadership in translational research—bringing molecular discoveries closer to clinical application.”
Find more insights here.
Stay updated on the emerging in the field of platelet disorders with Hemostasis Today.
-
Nov 4, 2025, 09:26Courtney Lawrence: One of Our Most Popular American Red Cross SUCCESS Talks is Just Around the Corner!
-
Nov 4, 2025, 09:21New Study by Emmanuel J Favaloro and Team Questions Consistency in APS Classification and Diagnosis
-
Nov 4, 2025, 09:20Yazan Abou Ismail to Present Insights on AI Models in TTP at 67th ASH Annual Meeting
-
Nov 4, 2025, 09:17David Calvet Canut on Takeda's HyHub: A Shift Toward Patient-Centered Biologics
-
Nov 4, 2025, 09:16Samantha Nelson Encourages You to Share Your Experience on World Thrombosis Day
-
Nov 4, 2025, 08:57Toluwalase Awoyemi: Digital Health Meets Maternal Heart Care
-
Nov 4, 2025, 08:53Rebecca Ahrens Nicklas Shares FDA Interactions on Interventional Genetics with The Rare Disease Community
-
Nov 3, 2025, 09:13Claudio Carrubba on How Timing Truly Matters in Trauma Embolization
-
Nov 3, 2025, 08:57Multiplex Apolipoprotein Panel Boosts Cardiovascular Risk Prediction and Precision Therapy
-
Nov 3, 2025, 08:46Rachel Lamerton and Colleagues on Activation of Platelets in Flow Cytometry
-
Nov 4, 2025, 09:10OCCUPI Trial Analysis Highlights Benefits of OCT Guidance in ACS Patients
-
Oct 29, 2025, 07:31The Use of Artificial Intelligence to Improve Detection of Acute Incidental Pulmonary Emboli - JTH
-
Oct 29, 2025, 07:05Shrinidhi Nathany: AI in Diagnostic Medicine
-
Oct 28, 2025, 07:02Aya Berman: AI Model for Predicting Bacteremia
-
Oct 28, 2025, 06:55The New Era of Genomics, AI and Cell Therapy in Hematology and Infectious Diseases
-
Nov 4, 2025, 09:17HaemophiliaIRL Series Begins․ Advances in von Willebrand Disease Treatment
-
Nov 4, 2025, 09:14Exploring Molecular Pathways of Aging in Hematopoiesis․ FEBS Workshop 2025
-
Nov 4, 2025, 08:28Fritz Roth Thanks Supporters of Science Magazine Study Linking Genes to High Cholesterol and Heart Attack Risk
-
Nov 4, 2025, 08:22Colleen Silk on Novo Nordisk Taking the 2025 Prix Galien US Award
-
Nov 4, 2025, 08:14Cristina Anton: Excited to Be Part of Women in Hematology!